INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasive diagnostics using its proprietary exosome development technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.
Frequently asked questions
What sector does INOVIQ LTD. (EGQ0) operate in?
INOVIQ LTD. belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is INOVIQ LTD. (EGQ0) current stock price?
As of the latest data, INOVIQ LTD. stock price is €0.08, with a previous close of €0.08. INOVIQ LTD. gained €0.00 in the last trading session, representing a 0.63% increase.
What is INOVIQ LTD. (EGQ0) current market capitalization?
INOVIQ LTD. market cap is approximately 11.19 million.
What is INOVIQ LTD. (EGQ0) Earnings Per Share (EPS)?
The trailing EPS is -€0.04.
Does INOVIQ LTD. (EGQ0) pay dividends?
No. INOVIQ LTD. does not pay a dividend.
What is INOVIQ LTD. (EGQ0) beta (volatility) score?
INOVIQ LTD. has a beta of 1.540, suggesting it is more volatile than the market.